GURUFOCUS.COM » STOCK LIST » Financial Services » Asset Management » abrdn Life Sciences Investors (NYSE:HQL) » Definitions » Earnings Yield %
中文

abrdn Life Sciences Investors (abrdn Life Sciences Investors) Earnings Yield % : 6.02% (As of Apr. 25, 2024)


View and export this data going back to . Start your Free Trial

What is abrdn Life Sciences Investors Earnings Yield %?

The earnings yield is an indication of how much return shareholders' investment in the company earned over the past 12 months. The higher the earnings yield is, the better.

As of today (2024-04-25), the stock price of abrdn Life Sciences Investors is $13.12. abrdn Life Sciences Investors's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Sep. 2023 was $0.79. Therefore, abrdn Life Sciences Investors's earnings yield of today is 6.02%.

The earnings yield does not consider the growth of the business. A better indicator of the attractiveness of an investment which takes growth into account is the Forward Rate of Return (Yacktman) %. abrdn Life Sciences Investors's Forward Rate of Return (Yacktman) % for the quarter that ended in Sep. 2023 was -5.24%. The Forward Rate of Return uses the normalized Free Cash Flow of the past seven years, and considers growth. The forward rate of return can be thought of as the return that investors buying the stock today can expect from it in the future.


abrdn Life Sciences Investors Earnings Yield % Calculation

Earnings yield is the reciprocal of the P/E Ratio.

abrdn Life Sciences Investors's Earnings Yield for today is calculated as

Earnings Yield=Earnings per Share (Diluted) (TTM)/Share Price
=0.790/13.12
=6.02 %

For company reported semi-annually, abrdn Life Sciences Investors's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Sep. 2023 adds up the semi-annually data reported by the company within the most recent 12 months, which was $0.790 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

It can also be calculated from the numbers for the whole company:

Earnings Yield=Net Income /Market Cap

The earnings in the calculation is the Trailing Twelve Months earnings.


abrdn Life Sciences Investors  (NYSE:HQL) Earnings Yield % Explanation

If the P/E ratio is an indication of how many years it takes for the company to earn back the stock price shareholders pay to buy the shares, the earnings yield is an indication of how much return shareholders' investment in the company earned over the past 12 months. The higher the earnings yield is, the better.

If a company loses money, the earnings yield is negative. This gives a more straightforward indication that the company is losing money. This is an advantage of using earnings yield instead of the P/E ratio in valuation. For valuation purposes, the P/B Ratio and the P/S Ratio should be used for companies that are losing money.

Like the P/E ratio, the earnings yield can be used to compare investments in different industries. It can even be used to compare the attractiveness of different asset classes such as bonds and cash. Of course, the earnings yield should not be the only factor in deciding which asset classes to invest.

Also similar to the P/E ratio, the earnings yield does not consider the growth of the business. A growing company with the same earnings yield should be more attractive than a company that has the same earnings yield but does not grow.

A better indicator of the attractiveness of an investment which takes growth into account is the Forward Rate of Return (Yacktman) %.

Be Aware

Just like the P/E Ratio, non-recurring items such as selling part of the business, selling a previous investment, etc., can affect earnings yield dramatically. The earning yield is also a poor indication for cyclical companies. When a cyclical stock has a high earnings yield it is usually at the peak of its cycle.


abrdn Life Sciences Investors Earnings Yield % Related Terms

Thank you for viewing the detailed overview of abrdn Life Sciences Investors's Earnings Yield % provided by GuruFocus.com. Please click on the following links to see related term pages.


abrdn Life Sciences Investors (abrdn Life Sciences Investors) Business Description

Traded in Other Exchanges
N/A
Address
1900 Market Street, Suite 200, Philadelphia, PA, USA, 19103
abrdn Life Sciences Investors operates as a non-diversified closed-end management investment company. Its investment objective is to seek long-term capital appreciation by investing primarily in securities of Life Sciences companies. It invests in securities of public and private companies that are believed by the Fund's Investment Adviser, abrdn Inc to have significant potential for above-average growth.
Executives
Todd Reit director C/O ABERDEEN STANDARD INVESTMENTS, 1900 MARKET STREET, SUITE 200, PHILADELPHIA PA 19103
Bill Maher director 600 WEST BROADWAY, 30TH FL., SAN DIEGO CA 92101
Rose Dimartino director C/O ABRDN, 1900 MARKET STREET, PHILADELPHIA PA 19103
James Joseph O'connor other: Director of Adviser C/O ABERDEEN STANDARD INVESTMENTS, 1900 MARKET STREET, SUITE 200, PHILADELPHIA PA 19103
Marika Tooze other: Director of Adviser C/O ABRDN, 1900 MARKET STREET, SUITE 200, PHILADELPHIA PA 19103
Aberdeen Standard Investments Inc. other: Adviser 1900 MARKET ST., 2ND FLOOR, PHILADELPHIA PA 19103
Jaclyn Marie Matsick other: Director of Adviser C/O ABRDN, 1900 MARKET STREET, SUITE 200, PHILADELPHIA PA 19103
Lucia Sitar officer: VP and Chief Legal Officer 1735 MARKET STREET, 32ND FLOOR, PHILADELPHIA PA 19103
Jennifer A Nichols other: Director of Adviser 1735 MARKET STREET, 37TH FLOOR, PHILADELPHIA PA 19103
Christian Pittard officer: President ONE BOW CHURCHYARD, LONDON X0 EC4M 9HH
Megan Kennedy officer: Secretary and Vice President 1735 MARKET STREET, 32ND FLOOR, PHILADELPHIA PA 19103
Sharon Ferrari officer: Treasurer and CFO 1735 MARKET STREET, 32ND FLOOR, PHILADELPHIA PA 19103
Alan R Goodson officer: Vice President 1735 MARKET STREET, 32ND FLOOR, PHILADELPHIA PA 19103
Joseph Andolina officer: Chief Compliance Officer & VP 1735 MARKET STREET, 32ND FLOOR, PHILADELPHIA PA 19103
Stephen Bird director 388 GREENWICH STREET, 17TH FLOOR, NEW YORK NY 10022

abrdn Life Sciences Investors (abrdn Life Sciences Investors) Headlines

From GuruFocus

Tekla Life Sciences Investors Declares Distribution

By Business Wire Business Wire 11-15-2022

Tekla Life Sciences Investors Declares Distribution

By Business Wire Business Wire 08-16-2022

Tekla Life Sciences Investors Declares Distribution

By Business Wire Business Wire 11-16-2020

Tekla Life Sciences Investors Declares Stock Distribution

By Business Wire Business Wire 05-18-2021

Tekla Life Sciences Investors Declares Distribution

By Business Wire 08-15-2023

Tekla Life Sciences Investors Paid Distribution

By Business Wire Business Wire 12-31-2021

Tekla Life Sciences Investors Paid Distribution

By Business Wire Business Wire 09-30-2021

Tekla Life Sciences Investors Paid Distribution

By Business Wire Business Wire 06-30-2022

Tekla Life Sciences Investors Paid Distribution

By Business Wire Business Wire 06-30-2021

Tekla Life Sciences Investors Declares Cash Distribution

By Business Wire Business Wire 12-22-2020